Ono Pharmaceutical: Pipeline * Products * Performance * Potential
|出版日||ページ情報||英文 60 Pages
|小野薬品工業：パイプライン、製品、実績、潜在能力 Ono Pharmaceutical: Pipeline * Products * Performance * Potential|
|出版日: 2011年04月30日||ページ情報: 英文 60 Pages||
Fiscal 2009 was another difficult period for Ono. Historically, the company markets products for niche indications, ensuring low competition and steady sales. However, recent governmental price cuts and the implementation of various healthcare cost containment policies have hit the company hard, leading to declines in revenue and income. Ono is not the only Japanese company to be impacted by these factors, several of its competitors have entered into mergers to strengthen their position. In recent years, five major mergers have occurred in Japan to form Dainippon Sumitomo Pharma (Dainippon and Sumitomo Pharmaceutical), Astellas Pharma (Yamanouchi and Fujisawa), Mitsubishi-Tanabe Pharma (Mitsubishi Pharma and Tanabe), Daiichi Sankyo (Daiichi and Sankyo Pharmaceutical) and most recently, Kyowa Hakko Kirin (Kyowa Hakko and Kirin Brewery). Ono has not announced any merger intentions, which places the company in a vulnerable position.
If Ono is to emerge from this difficult period, the company will have to rapidly overhaul its product portfolio to market products with forecasted long-term growth. To this end, Ono established its Strategic Alliance division in 2007. This business segment is actively seeking collaborations around the globe in order to expand the pipeline through licensing agreements and bring candidate compounds to market more rapidly through research alliances. Agreements with Merck & Co, Novartis and Astellas have seen the pipeline bolstered by additions of Glactiv, Rivastach Patch and Recalbon, which are forecast to make strong contributions to company revenue. Drug development in Japan is focused on obtaining early approval for late-stage compounds, leveraged by results from multinational clinical trials and other international studies. Ono is also focused on acquiring commercialisation rights to new drug candidates. Gaining new drug approvals in Europe and the US, particularly in areas of unmet medical need, remains a key focus for Ono.
As one of the smaller players in the Japanese market, and certainly globally, a portfolio overhaul may not be sufficient to maintain Ono' s centuries old business. Ono should consider combining its aggressive licensing and collaborative strategy with a major pharmaceutical merger if it is to return to sales growth.
Sales of Top Ten Products (2008-2016)
But what' s in the pipeline?
For the full story on Ono Pharmaceutical' s challenges and opportunities order this important strategic analysis today
This new strategic report provides a detailed analysis of Ono Pharmaceutical' s competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.
Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
THERAPEUTIC AREA FOCUS